Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(8):628; doi:10.1093/jnci/95.8.628
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vincent-Salomon, A.
Right arrow Articles by Mathoulin-Pélissier, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vincent-Salomon, A.
Right arrow Articles by Mathoulin-Pélissier, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 8, 628, April 16, 2003
© 2003 Oxford University Press

CORRESPONDENCE

Re: HER2 Testing in the Real World

Anne Vincent-Salomon, Gaëtan MacGrogan, Jérôme Couturier, Laurent Arnould, Simone Mathoulin-Pélissier
Groupe d’Etude des Facteurs Pronostiques par Immunohistochime dans les Cancers du Sein (GEFPICS)

Affiliations of authors: A. Vincent-Salomon, J. Couturier, Institut Curie, Paris, France; G. MacGrogan, S. Mathoulin-Pélissier, Institut Bergonié, Bordeaux, France; L. Arnould, Institut Georges-François Leclerc, Dijon, France.

Correspondence to: Anne Vincent-Salomon, M.D., Institut Curie, 26 rue d’Ulm, 75248 Paris Cedex 05, France (anne.salomon@curie.net).

The first 10% of the full text of this article appears below.

We read with interest the recent studies by Paik et al. (1) and Roche et al. (2) that dealt with some of the problems with immunohistochemical (IHC) testing for the HER2 protein. We fully support the view expressed by Dr. Zujewski (3) in the editorial that accompanied these two studies regarding the need to "build quality in" when performing such assays. Because trastuzumab targets . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
L. Arnould, P. Arveux, J. Couturier, M. Gelly-Marty, C. Loustalot, F. Ettore, C. Sagan, M. Antoine, F. Penault-Llorca, B. Vasseur, et al.
Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification
Clin. Cancer Res., November 1, 2007; 13(21): 6404 - 6409.
[Abstract] [Full Text] [PDF]